Accelovance Announces Opening Offices in China at Maryland Beijing Reception

    BEIJING, May 4 /PRNewswire/ -- Accelovance, a Rockville, Maryland based
 company with a wholly foreign owned enterprise (WFOE) in China held its
 Accelovance (China) office Grand Opening ribbon cutting ceremony as part of
 Maryland Beijing Reception last Thursday.  This is a key step in the company's
 strategy to bring a global solution to meeting trial timelines.  The Beijing
 office will serve as the base of operations for clinical sites scheduled to be
 functioning within 9 months.  Sites in China will provide Accelovance's
 clients with a strategic alternative to their clinical trial needs and will
 add to the existing 12-site network in the United States.
     In attendance were 150 guests including representatives from China's
 Ministry of Foreign Affairs, Ministry of Health, State Food & Drug
 Administration, Ministry of Science & Technology, Beijing municipal
 government, as well as representatives from clinical research centers, global
 pharmaceutical companies and Chinese pharmaceutical industry.  This event
 brought further attention to the continued promotion of the business
 collaboration between the State of Maryland and China.
     "We are very excited to be starting our China operations and to be part of
 the growing collaboration between Maryland and China," commented Accelovance
 President and CEO, Stephen J. Trevisan.  "China brings tremendous value to
 clinical trial performance.  There is a wealth of highly qualified and
 talented researchers, patients can be enrolled rapidly, and trials can be
 conducted in a very cost effective manner."
     Dr. Ken Ren, President of Accelovance China agreed, "We are closer to
 fulfilling our vision of becoming a global trial management organization.
 With the growing compliance with international GCP standards, the large number
 of well-educated and experienced investigators, and huge treatment-naive
 patient population, China represents one the most attractive areas for
 conducting global clinical trials for new drug development."
 
     Headquartered in Rockville, Maryland, Accelovance is a privately held
 company that has 12 clinical sites in the United States.  In China, the
 Company will operate through its wholly-owned enterprise in Beijing and
 establish clinical site networks in the country.  Accelovance provides Phase
 II-IV clinical trial services across a breadth of therapeutic areas that
 include investigator selection, patient recruitment and study management
 services for pharmaceutical, contract research organization (CRO), and
 biotechnology industries.  The company is focused on optimizing the quality
 and productivity of multiple clinical sites, through strong central management
 and targeted pro-active patient recruitment.  Delivering high quality and
 timely clinical trial support services, Accelovance is committed to
 understanding and meeting its clients needs to ensure their success.
     For more information, visit the company's website at
 http://www.accelovance.com.
 
     CONTACT: Media: Garrett D. Smith at 301.222.2212
 
 

SOURCE  Accelovance